The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
The BRET technology and its application to screening assays
Abstract
The bioluminescence resonance energy transfer (BRET) method is based on resonance energy transfer between a light‐emitting enzyme and a fluorescent acceptor. Since its first description in 1999, several versions of BRET have been described using different substrates and energy donor/acceptor couples. Today, BRET is considered as one of the most versatile techniques for studying the dynamics of protein‐protein interactions in living cells. Various studies have applied BRET‐based assays to screen new receptor ligands and inhibitors of disease‐related‐proteases. Inhibitors of protein‐protein interactions are likely to become a new major class of therapeutic drugs, and BRET technology is expected to play an important role in the identification of such compounds. This review describes the original BRET‐based methodology, more recent variants, and potential applications to drug screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shaner, N. C., Campbell, R. E., Steinbach, P. A., Giepmans, B. N. G., Palmer, A. E., & Tsien, R. Y. (2004) · Nature Biotechnology · doi:10.1038/nbt1037 · Cited by 4,619
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Hamdan, F. F., Audet, M., Garneau, P., Pelletier, J., & Bouvier, M. (2005) · SLAS Discovery · doi:10.1177/1087057105275344 · Cited by 183 · cited 4×
“Several other variants of the YFP with identical excitatory properties are YFP topaz [21, 34, 36–38], YFP citrine [29, 32, 39], YFP venus [40, 41] and YPet [42, 43].”
BackgroundMethodInfluentialNew assay technologies for high-throughput screening
Silverman, L., Campbell, R., & Broach, J. R. (1998) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(98)80015-x · Cited by 151 · cited 1×
“Reporter gene assays have been used to monitor receptor activation [72–75].”
MethodNutlin-3 inhibits the NFκB Pathway in a p53 Dependent Manner: Implications in Lung Cancer Therapy
Dey, A., Wong, E. T., Bist, P., Tergaonkar, V., & Lane, D. (2007) · Cell Cycle · doi:10.4161/cc.6.17.4643 · Cited by 70
Meslet-Cladiére, L., Norais, C., Kuhn, J., Briffotaux, J., Sloostra, J. W., Ferrari, E., Hübscher, U., Flament, D., & Myllykallio, H. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.06.056 · Cited by 54
Cited by
G Protein–Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives
Ferré, S., Casadó, V., Devi, L. A., Filizola, M., Jockers, R., Lohse, M. J., Milligan, G., Pin, J.-P., & Guitart, X. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008052 · Cited by 570
Self-citationModulators of Protein–Protein Interactions
Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497
Phenotypic screens as a renewed approach for drug discovery
Zheng, W., Thorne, N., & McKew, J. C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.001 · Cited by 423
Chen, B., Yu, P., Chan, W. N., Xie, F., Zhang, Y., Liang, L., Leung, K. T., Lo, K. W., Yu, J., Tse, G. M. K., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01679-y · Cited by 420
Genetically Encodable Fluorescent Biosensors for Tracking Signaling Dynamics in Living Cells
Newman, R. H., Fosbrink, M. D., & Zhang, J. (2011) · Chemical Reviews · doi:10.1021/cr100002u · Cited by 353
Metadata
- Authors
- Bacart, J., Corbel, C., Jockers, R., Bach, S., & Couturier, C.
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2008-03
- Volume
- 3
- Issue
- 3
- Pages
- 311-324
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W2147476348
- Cited by
- 178
- References
- 6
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.